HK1184432A1 - Process for preparing intermediates of compounds useful as opioid receptor modulators - Google Patents

Process for preparing intermediates of compounds useful as opioid receptor modulators

Info

Publication number
HK1184432A1
HK1184432A1 HK13111031.3A HK13111031A HK1184432A1 HK 1184432 A1 HK1184432 A1 HK 1184432A1 HK 13111031 A HK13111031 A HK 13111031A HK 1184432 A1 HK1184432 A1 HK 1184432A1
Authority
HK
Hong Kong
Prior art keywords
compounds useful
opioid receptor
receptor modulators
preparing intermediates
intermediates
Prior art date
Application number
HK13111031.3A
Other languages
English (en)
Chinese (zh)
Inventor
Chaozhong Cai
Wei He
Robert W Kavash
Henry J Breslin
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1184432(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HK1184432A1 publication Critical patent/HK1184432A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
HK13111031.3A 2004-03-15 2013-09-27 Process for preparing intermediates of compounds useful as opioid receptor modulators HK1184432A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55334204P 2004-03-15 2004-03-15

Publications (1)

Publication Number Publication Date
HK1184432A1 true HK1184432A1 (en) 2014-01-24

Family

ID=34962827

Family Applications (4)

Application Number Title Priority Date Filing Date
HK07105593.3A HK1099016A1 (en) 2004-03-15 2007-05-28 Novel compounds as opioid receptor modulators
HK07111210.4A HK1105967A1 (en) 2004-03-15 2007-10-17 Novel compounds as opioid receptor modulators
HK11109830.2A HK1155726A1 (en) 2004-03-15 2011-09-19 Opioid receptor modulators
HK13111031.3A HK1184432A1 (en) 2004-03-15 2013-09-27 Process for preparing intermediates of compounds useful as opioid receptor modulators

Family Applications Before (3)

Application Number Title Priority Date Filing Date
HK07105593.3A HK1099016A1 (en) 2004-03-15 2007-05-28 Novel compounds as opioid receptor modulators
HK07111210.4A HK1105967A1 (en) 2004-03-15 2007-10-17 Novel compounds as opioid receptor modulators
HK11109830.2A HK1155726A1 (en) 2004-03-15 2011-09-19 Opioid receptor modulators

Country Status (36)

Country Link
US (8) US7741356B2 (xx)
EP (5) EP3112352B1 (xx)
JP (1) JP4778954B2 (xx)
KR (1) KR101166342B1 (xx)
CN (2) CN1950342B (xx)
AR (2) AR048269A1 (xx)
AT (1) ATE516274T1 (xx)
AU (1) AU2005224091B2 (xx)
BR (1) BRPI0508820B8 (xx)
CA (1) CA2560047C (xx)
CR (1) CR8655A (xx)
CY (3) CY1111927T1 (xx)
DK (5) DK2653465T3 (xx)
EC (1) ECSP066856A (xx)
ES (5) ES2367576T3 (xx)
HK (4) HK1099016A1 (xx)
HR (4) HRP20110694T1 (xx)
HU (2) HUE029852T2 (xx)
IL (3) IL178040A (xx)
LT (2) LT2653465T (xx)
LU (1) LUC00007I2 (xx)
ME (3) ME02221B (xx)
MX (1) MXPA06010642A (xx)
MY (1) MY146972A (xx)
NL (1) NL300865I2 (xx)
NO (3) NO338203B1 (xx)
NZ (1) NZ549842A (xx)
PH (1) PH12012501640A1 (xx)
PL (4) PL2298744T3 (xx)
PT (4) PT2298744E (xx)
RS (4) RS54199B1 (xx)
SI (4) SI2573068T1 (xx)
TW (1) TWI361069B (xx)
UA (1) UA86053C2 (xx)
WO (1) WO2005090315A1 (xx)
ZA (1) ZA200608587B (xx)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
EP3112352B1 (en) * 2004-03-15 2018-11-21 Janssen Pharmaceutica NV Opioid receptor modulators
JP5420170B2 (ja) 2004-05-14 2014-02-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ カルボキサミド系オピオイド化合物
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
RS53873B1 (en) * 2005-03-14 2015-08-31 Janssen Pharmaceutica Nv PROCEDURE FOR PREPARING OPIOID MODULATORS
US7626039B2 (en) * 2005-12-14 2009-12-01 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors
NZ569293A (en) 2005-12-23 2011-10-28 Zealand Pharma As Modified lysine-mimetic compounds
US7973142B2 (en) 2006-04-07 2011-07-05 Warner Chilcott Company Antibodies that bind human protein tyrosine phosphatase beta (HPTPβ)
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
PL2468724T3 (pl) 2006-12-21 2016-05-31 Zealand Pharma As Synteza związków pirolidynowych
SG185941A1 (en) * 2007-07-09 2012-12-28 Janssen Pharmaceutica Nv Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid
EP2182983B1 (en) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
TWI468375B (zh) 2008-10-27 2015-01-11 Janssen Pharmaceutica Nv 製備經保護之ｌ－丙胺酸衍生物之方法
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP5198220B2 (ja) * 2008-11-13 2013-05-15 東ソ−・エフテック株式会社 アミノ酸誘導体の製造方法
PL2451279T3 (pl) 2009-07-06 2019-09-30 Aerpio Therapeutics, Inc. Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych
EP2524912A1 (en) 2011-05-16 2012-11-21 Bionomics Limited Amine derivatives
WO2012155199A1 (en) 2011-05-16 2012-11-22 Bionomics Limited Amine derivatives as potassium channel blockers
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9023883B2 (en) 2013-03-14 2015-05-05 Epizyme, Inc. PRMT1 inhibitors and uses thereof
US9447079B2 (en) * 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
CN105339351B (zh) 2013-03-14 2018-11-06 Epizyme股份有限公司 精氨酸甲基转移酶抑制剂及其用途
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
WO2017007695A1 (en) 2015-07-09 2017-01-12 The Regents Of The University Of California Mu opioid receptor modulators
EP3325450A1 (en) 2015-07-23 2018-05-30 Teva Pharmaceuticals International GmbH Solid state forms of eluxadoline
WO2017043626A1 (ja) * 2015-09-11 2017-03-16 株式会社カネカ 光学活性４－カルバモイル－２，６－ジメチルフェニルアラニン誘導体の製造法
CA2998673C (en) 2015-09-23 2023-12-12 Aerpio Therapeutics, Inc. Methods of treating intraocular pressure with activators of tie-2
CN105250232B (zh) * 2015-09-29 2018-08-14 江苏汇智知识产权服务有限公司 一种伊卢多啉肠溶片及其制备方法
WO2017114446A1 (zh) * 2015-12-31 2017-07-06 苏州晶云药物科技有限公司 艾沙度林的新晶型及其制备方法
CN107129444B (zh) * 2016-02-29 2018-08-31 尚科生物医药（上海）有限公司 (s)-2-叔丁氧羰基氨基-3-(4-氨甲酰基-2,6-二甲基苯基)丙酸制备方法
EP3272741A1 (en) 2016-07-21 2018-01-24 Euticals S.P.A. New stable solvate crystalline forms of eluxadoline
CN105777584B (zh) * 2016-03-28 2018-01-02 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
CN105693554B (zh) * 2016-04-06 2017-08-08 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
WO2017191650A1 (en) * 2016-05-03 2017-11-09 Msn Laboratories Private Limited Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino]methyl-2-methoxybenzoic acid and its polymorphs thereof
US20190177282A1 (en) * 2016-05-30 2019-06-13 Sun Pharmaceutical Industries Limited A process for the preparation of eluxadoline
US10822308B2 (en) * 2016-06-23 2020-11-03 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018020450A2 (en) 2016-07-28 2018-02-01 Lupin Limited Process for the preparation of eluxadoline
CZ2016548A3 (cs) 2016-09-07 2018-03-14 Zentiva, K.S. Pevné formy eluxadolinu
WO2018047131A1 (en) * 2016-09-09 2018-03-15 Sun Pharmaceutical Industries Limited Amorphous eluxadoline
US10479769B2 (en) 2016-09-20 2019-11-19 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018138272A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline form and process for the preparation thereof
WO2018138274A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline forms and processes for their preparation
WO2018202865A1 (en) 2017-05-05 2018-11-08 Zealand Pharma A/S Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
WO2019008604A1 (en) 2017-07-07 2019-01-10 Cipla Limited NEW FORMS OF MU-OPIOID RECEPTOR AGONIST
WO2019144805A1 (zh) * 2018-01-25 2019-08-01 四川科伦博泰生物医药股份有限公司 取代的苯乙胺化合物及其制备方法和用途
WO2019197274A1 (en) 2018-04-09 2019-10-17 Quimica Sintetica, S. A. Process for the preparation of opioid modulators
CA3109557A1 (en) 2018-08-20 2020-02-27 Allergan Holdings Unlimited Company Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
CN113164597A (zh) 2018-09-24 2021-07-23 爱尔皮奥制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
EP3659433B1 (de) * 2018-11-30 2021-01-20 Phytobiotics Futterzusatzstoffe GmbH System zur analyse von tierausscheidungsbildern
CN111377832A (zh) * 2018-12-27 2020-07-07 江苏联昇化学有限公司 一种伊卢多啉中间体制备的新方法
EP3962482A4 (en) 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. TIE-2 ACTIVATORS TARGETING THE SCHLEMM CHANNEL
US20230118152A1 (en) 2020-03-30 2023-04-20 Allergan Holdings Unlimited Company Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
IL300110A (en) * 2020-07-28 2023-03-01 Jazz Pharmaceuticals Ireland Ltd Chiral synthesis of RAF inhibitors in compressed cyclics
US11850319B2 (en) 2020-09-29 2023-12-26 Abl Ip Holding Llc Techniques for directing ultraviolet energy towards a moving surface
US20220096676A1 (en) 2020-09-29 2022-03-31 Abl Ip Holding Llc Techniques for Directing Ultraviolet Energy Towards a Moving Surface
CN114163348A (zh) * 2020-11-27 2022-03-11 成都泰蓉生物科技有限公司 一种氨酰基取代的l-苯丙氨酸的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD142804A3 (de) * 1977-11-07 1980-07-16 Wagner Guenter Verfahren zur herstellung von na-alkyl-bzw.na-aryl-sulfonylierten omega-amidinophenyl-alpha-aminoalkylcarbonsaeureamiden
US4879398A (en) * 1987-12-31 1989-11-07 Monsanto Company Process for producing 2,6-disubstituted tyrosine
SE9402880D0 (sv) 1994-08-30 1994-08-30 Astra Ab New peptide derivatives
CZ238197A3 (en) * 1995-01-27 1997-12-17 Novo Nordisk As Growth hormone formation stimulating compounds
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
ATE277021T1 (de) 1995-04-13 2004-10-15 Aventis Pharma Inc Neue substituierte piperazinderivate mit tachykininrezeptor-antagonistischer wirkung
EP0761220A1 (en) 1995-08-21 1997-03-12 Eli Lilly And Company 2-Acylaminopropanamides as growth hormone secretagogues
AU7710596A (en) 1995-11-29 1997-06-19 Nihon Nohyaku Co., Ltd. Phenylalanine derivatives, optically active substances, salts or coordination compounds thereof, and their use as fungicides
US5792760A (en) 1997-04-23 1998-08-11 Eli Lilly And Company Bisindoles as tachykinin receptor antagonists
IT1304898B1 (it) 1998-09-08 2001-04-05 Menarini Ricerche Spa Prodotti con caratteristiche basiche aventi attivita' antagonista sulrecettore nk-1 e loro impiego in preparazioni farmaceutiche
ES2206139T3 (es) * 1999-05-28 2004-05-16 Pfizer Products Inc. Derivados de 3-(3-hidrofenil)-3-amino-propionamida.
FR2796643B1 (fr) 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
GB0021419D0 (en) 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
US20020072017A1 (en) * 2000-10-19 2002-06-13 Hudnall Phillip Montgomery Stabilized p-phenylenediamine-type photographic color developers in free base form
AU2479702A (en) 2000-10-30 2002-05-15 Janssen Pharmaceutica Nv Tripeptidyl peptidase inhibitors
DE60216627T2 (de) * 2001-10-15 2007-09-20 Janssen Pharmaceutica N.V. Neue substituierte 4-phenyl-4-ä1h-imidazo-2-ylü-piperidin-derivate und ihre anwendung als selective delta-opioid-agonisten
US7041681B2 (en) 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
EP3112352B1 (en) * 2004-03-15 2018-11-21 Janssen Pharmaceutica NV Opioid receptor modulators
US7282507B2 (en) 2004-05-03 2007-10-16 Janssen Pharmaceutica N.V. Indole derivatives as selective androgen receptor modulators (SARMS)
RS53873B1 (en) * 2005-03-14 2015-08-31 Janssen Pharmaceutica Nv PROCEDURE FOR PREPARING OPIOID MODULATORS

Also Published As

Publication number Publication date
US9205076B2 (en) 2015-12-08
CA2560047A1 (en) 2005-09-29
ES2428008T3 (es) 2013-11-05
ES2367576T3 (es) 2011-11-04
EP1725537A1 (en) 2006-11-29
PT2298744E (pt) 2013-09-12
US10213415B2 (en) 2019-02-26
PT1725537E (pt) 2011-09-08
ECSP066856A (es) 2006-11-24
CY2017008I1 (el) 2017-11-14
IL178040A0 (en) 2006-12-31
US9700542B2 (en) 2017-07-11
AU2005224091A1 (en) 2005-09-29
PT2653465T (pt) 2016-09-22
US8772325B2 (en) 2014-07-08
HRP20150305T1 (hr) 2015-04-24
US7786158B2 (en) 2010-08-31
HUS1700010I1 (hu) 2017-03-28
PL1725537T3 (pl) 2011-12-30
LUC00007I2 (xx) 2017-05-02
ATE516274T1 (de) 2011-07-15
DK3112352T3 (en) 2019-01-28
US20050203143A1 (en) 2005-09-15
PL2298744T3 (pl) 2013-11-29
SI2573068T1 (sl) 2015-03-31
CN1950342B (zh) 2012-09-26
EP2653465B1 (en) 2016-07-13
ES2596434T3 (es) 2017-01-09
PL2573068T3 (pl) 2015-06-30
HRP20161331T1 (hr) 2016-12-30
MXPA06010642A (es) 2007-03-26
PH12012501640B1 (en) 2015-10-05
NL300865I1 (nl) 2017-03-14
US8344011B2 (en) 2013-01-01
RS51995B (en) 2012-04-30
KR101166342B1 (ko) 2012-07-18
IL178040A (en) 2013-12-31
WO2005090315A1 (en) 2005-09-29
US20100324051A1 (en) 2010-12-23
US7741356B2 (en) 2010-06-22
SI1725537T1 (sl) 2011-11-30
ME02540B (me) 2017-02-20
DK2573068T3 (en) 2015-02-16
RS55122B1 (sr) 2016-12-30
AU2005224091B2 (en) 2012-02-02
MY146972A (en) 2012-10-15
CN1950342A (zh) 2007-04-18
LT2653465T (lt) 2016-09-12
ES2533176T3 (es) 2015-04-08
SI2298744T1 (sl) 2013-10-30
ES2705077T3 (es) 2019-03-21
BRPI0508820B1 (pt) 2018-04-10
DK1725537T3 (da) 2011-10-31
EP2653465A1 (en) 2013-10-23
CA2560047C (en) 2013-12-24
EP2298744A3 (en) 2011-08-10
HK1105967A1 (en) 2008-02-29
ME02221B (me) 2016-02-20
HRP20110694T1 (hr) 2011-12-31
NO20064660L (no) 2006-12-14
BRPI0508820B8 (pt) 2022-11-29
IL224908A (en) 2015-07-30
HK1099016A1 (en) 2007-08-03
BRPI0508820A (pt) 2007-08-07
EP1725537B1 (en) 2011-07-13
CY2017008I2 (el) 2017-11-14
CY1118096T1 (el) 2017-06-28
PL2653465T3 (pl) 2017-01-31
IL229444A0 (en) 2013-12-31
JP2007529527A (ja) 2007-10-25
PT2573068E (pt) 2015-04-27
US20180325870A1 (en) 2018-11-15
EP2573068B9 (en) 2015-08-26
SI2653465T1 (sl) 2016-10-28
TWI361069B (en) 2012-04-01
US20080096888A1 (en) 2008-04-24
IL229444A (en) 2017-03-30
CN102786476B (zh) 2017-01-18
EP3112352A1 (en) 2017-01-04
CY1111927T1 (el) 2015-11-04
HRP20130800T1 (xx) 2013-09-30
NL300865I2 (nl) 2020-08-17
US8609709B2 (en) 2013-12-17
NO20160916A1 (no) 2006-12-14
EP2573068A1 (en) 2013-03-27
CR8655A (es) 2008-09-09
NO2017007I2 (no) 2017-02-23
CN102786476A (zh) 2012-11-21
KR20060131983A (ko) 2006-12-20
AR095848A2 (es) 2015-11-18
EP2573068B1 (en) 2014-12-31
LTPA2017005I1 (lt) 2017-03-27
PH12012501640A1 (en) 2015-10-05
UA86053C2 (ru) 2009-03-25
US20160030393A1 (en) 2016-02-04
LUC00007I1 (xx) 2017-03-03
ME01601B (me) 2014-09-20
NZ549842A (en) 2010-10-29
US20140256779A1 (en) 2014-09-11
ZA200608587B (en) 2008-06-25
US20130090478A1 (en) 2013-04-11
NO338203B1 (no) 2016-08-08
HK1155726A1 (en) 2012-05-25
LTC1725537I2 (lt) 2018-02-26
DK2298744T3 (da) 2013-09-02
DK2653465T3 (da) 2016-08-22
RS52933B (en) 2014-02-28
US20140039024A1 (en) 2014-02-06
HUE029852T2 (en) 2017-04-28
EP3112352B1 (en) 2018-11-21
JP4778954B2 (ja) 2011-09-21
EP2298744A2 (en) 2011-03-23
NO2017007I1 (no) 2017-02-23
AR048269A1 (es) 2006-04-12
EP2298744B1 (en) 2013-06-26
RS54199B1 (en) 2015-12-31
TW200539876A (en) 2005-12-16

Similar Documents

Publication Publication Date Title
HK1184432A1 (en) Process for preparing intermediates of compounds useful as opioid receptor modulators
HRP20150417T1 (xx) Postupak za pripremu opioidnih modulatora
GB0615619D0 (en) Chemical process for preparation of intermediates
ZA200903889B (en) Process for the synthesis of moxifloxacin hydrochloride
HK1121453A1 (en) Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor 5-ht2a
HUP0500537A2 (en) Process for the preparation of rosuvastatin via new intermediates
GB0516603D0 (en) Processes for the preparation of organic compounds useful as serotonin receptor antagonists
PT1829872E (pt) Processo para produzir um composto indole
IL184715A0 (en) Process for the preparation of intermediates
HK1105968A1 (en) Process for production of 3-alkenylcephem compounds 3-
EP2081940A4 (en) PROCESS FOR THE PREPARATION OF PRULIFLOXACIN USING NEW INTERMEDIATE PRODUCTS
HK1100638A1 (en) Apparatus for preparing crystals of cremated remains
GB0525710D0 (en) An improved process for preparing of substituted 2-benzimidazolesulfoxide compounds
IL181721A0 (en) Process for preparing bicyclic pyrazolyl compounds
HK1142889A1 (en) A process for the preparation of intermediates of tetracyclic compounds
IL162071A0 (en) Process for synthesis of dinitrotetraoxadiazaisowurzitane (dtiw)
ZA200808813B (en) Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
EP2027105A4 (en) NEW PROCESS FOR PRODUCING INTERMEDIATE PRODUCTS FROM CCR ANTAGONISTS
GB0407724D0 (en) Process for preparing bicyclic compounds
HU2947U (en) Apparatus for producing of biogas

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230314